| Literature DB >> 32737133 |
Ahmad Khodr1, Florence Menard-Szczebara1, Laura Rushton2, Jean-Yves Maillard3, Sylvie Cupferman1, Eshwar Mahenthiralingam2.
Abstract
Burkholderia cepacia complex (Bcc) bacteria are intrinsically antimicrobial-resistant opportunistic pathogens and key risk species in the contamination of nonfood industrial products. New agents and formulations to prevent growth of Burkholderia in home care (cleaning agents) and personal-care (cosmetics and toiletries) products are required. We characterized how ethylzingerone [4-(3-ethoxy-4-hydroxyphenyl) butan-2-one] (HEPB) acts as a preservative with activity against Burkholderia species encountered in industry. Burkholderia (n = 58) and non-Burkholderia (n = 7) bacteria were screened for susceptibility to HEPB, and its mode of action and resistance were determined for a model Burkholderia vietnamiensis strain using transposon mutagenesis, transcriptomics, and genome resequencing analysis. The susceptibility of Burkholderia spp. to HEPB (MIC = 0.45% ± 0.11% [wt/vol]; MBC = 0.90% ± 0.3% [wt/vol]) was characterized, with limited inter- and intraspecies differences. HEPB (1% [wt/vol]) was rapidly bactericidal, producing a 6-log reduction in viability within 4 h. Spontaneous resistance to HEPB did not develop, but transient phenotypes with altered growth characteristics and susceptibility to antibiotics were identified after prolonged exposure to sublethal HEPB concentrations. Transposon mutagenesis and RNA-sequencing analysis identified multiple genetic pathways associated with HEPB exposure, including stress response mechanisms, altered permeability, regulation of intracellular pH, damage and repair of intracellular components, and alteration and repair of lipopolysaccharides. Key pathways included the stringent response, homeostasis of intracellular pH by the kdp operon, protection against electrophiles by KefC, and repair of oxidized proteins by methionine sulfoxide reductase enzymes. In summary, we show that HEPB has potent, targeted efficacy against Burkholderia bacteria without promoting wider stable antimicrobial resistance. The mode of action of HEPB against Burkholderia is multifactorial, but killing by intracellular oxidation is a key mechanism of this promising agent.IMPORTANCE Burkholderia bacteria are opportunistic pathogens that can overcome preservatives used in the manufacture of nonsterile industrial products and occasionally cause contamination. Consequently, new preservatives to prevent the growth of key risk Burkholderia cepacia complex bacteria in nonfood industrial products are urgently required. Here, we show that ethylzingerone is active against these problematic bacteria, killing them via a multifactorial mode of action which involves intracellular oxidation.Entities:
Keywords: Burkholderiazzm321990; ethylzingerone; genomics; mechanisms of resistance; preservative
Mesh:
Substances:
Year: 2020 PMID: 32737133 PMCID: PMC7499027 DOI: 10.1128/AEM.01808-20
Source DB: PubMed Journal: Appl Environ Microbiol ISSN: 0099-2240 Impact factor: 4.792
MIC and MBC of HEPB for Burkholderia and Paraburkholderia strains
| Genus or group ( | HEPB MIC (% [wt/vol]) | HEPB MBC (% [wt/vol]) | ||
|---|---|---|---|---|
| Median | Mean ± SD | Median | Mean ± SD | |
| 0.5 | 0.45 ± 0.12 | 1 | 0.90 ± 0.30 | |
| Bcc (54) | 0.5 | 0.46 ± 0.11 | 1 | 0.91 ± 0.29 |
| 0.125 | 0.125 | 0.5 | 0.625 ± 0.25 | |
Bcc, Burkholderia cepacia complex; n, number of strains. Median and mean values were derived from three biological replicate experiments. MIC and MBC data for individual strains are available in Table S3.
FIG 1Time-kill curves of B. vietnamiensis strain G4 and P. aeruginosa ATCC 19429 cultured in TSB with HEPB at concentrations below in-use levels. B. vietnamiensis strain G4 viability decreased to undetectable levels after exposure to 1% (wt/vol) HEPB for 1 h (data not shown). P. aeruginosa ATCC 19429 is indicated by dashed lines. Cultures were sampled over 1 week and neutralized before enumeration of viable cells. Data are means ± standard deviations (SD) for three biological replicates. The lower detection threshold was 103 CFU/ml. A final concentration of 2% (vol/vol) DMSO control did not reduce cell viability.
FIG 2Colony morphology and growth curve of B. vietnamiensis wild-type strain G4 and HEPB-adapted derivatives T2s and T3. (A) Colony morphology of wild-type (parental) strain and HEPB-adapted derivates cultured on TSA without HEPB for 24 h. HEPB-adapted derivatives form smaller discrete round colonies than the wild type. Bar, 2 mm. (B) Growth of the wild type and HEPB-adapted derivatives in TSB without HEPB and 0.375% (wt/vol) HEPB. Data are means ± SD for two biological replicates. Growth of T2s is similar to that of the wild-type in the absence of HEPB. HEPB-adapted derivatives reached higher final ODs than the wild-type in the presence of HEPB. Data for HEPB-adapted derivative T2L are not shown, as its colony morphology and growth in the absence and presence of HEPB were similar to those of the wild type.
Antibiotic susceptibility profiles of HEPB-adapted B. vietnamiensis strain G4 derivatives
| Strain | Mean MIC (μg/ml) of: | |||||||
|---|---|---|---|---|---|---|---|---|
| AMK | AZM | CIP | CHL | IPM | PIP | SXT | CAZ | |
| Parent (G4) | 1 | 4 | 0.19 | 12 | 0.125 | 0.5 | 0.125 | 0.5 |
| Derivative T2s | 1 | 4 | 0.19 | 32 | 0.125 | 0.5 | 0.19 | 0.38 |
| Derivative T2L | 1 | 3 | 0.19 | 12 | 0.125 | 0.5 | 0.19 | 0.5 |
| Derivative T3 | 0.25 | 1 | 0.64 | 24 | 0.16 | 0.25 | 0.125 | 0.25 |
Abbreviations: AMK, amikacin; AZM, azithromycin; CIP, ciprofloxacin; CHL, chloramphenicol; IPM, imipenem; PIP, piperacillin; SXT, trimethoprim-sulfamethoxazole; CAZ, ceftazidime. The antibiotic susceptibility profiles of HEPB-adapted derivatives before serial passage in the absence of HEPB are shown.
Transposon-interrupted genes of B. vietnamiensis strain G4 exhibiting altered susceptibility to HEPB and wild-type growth under control conditions
| Mutant ID | G4 DNA flanking transposon insertion site (20 bp) | Gene ID | Replicon | Mutated gene and putative function | COG category |
|---|---|---|---|---|---|
| 9:G3 | ACCCATCACCATGCCCACA | 4698 | chr2 | Amino acid transport and metabolism | |
| 44:B9 | CGTTCCGGCGCGGCGCTGCC | 6500 | chr3 | Cellulose synthase domain-containing protein | Carbohydrate transport and metabolism |
| 42:E3 | AAGTAAGACAGGTCACGAAC | 1471 | chr1 | RND efflux system outer membrane lipoprotein | Cell wall/membrane/envelope biogenesis |
| 14:C2 | AGCAGTTCATCGCGCTGGC | 0037 | chr1 | Type III restriction enzyme, res subunit | Defense mechanisms |
| 9:D8 | ATCGCTGACCACCCGCGCT | 0174 | chr1 | Hypothetical protein (putative restriction endonuclease) | Defense mechanisms |
| 5:D5 | CGGCTAGGCGGCCAGATCT | 3088 | chr1 | Energy production and conversion | |
| 43:B11 | AGGAGAAAGGCCCCGTCATC | 3033 | chr1 | 2-Oxoacid ferredoxin oxidoreductase | Energy production and conversion |
| 6:F3 | AGGCGGCCAGATCTGATCA | 7566 | pBVIE04 | Hypothetical protein | Function unknown |
| 9:D7 | CCCCCCCGTACTAGTCGAC | 3807 | chr2 | Amine oxidase | Function unknown |
| 19:E4 | CGCTGGCGGCCAGATCTGA | 1415 | chr1 | Hypothetical protein | Function unknown |
| 44:E6 | GTCAACGCGTGGCCAAATCG | 6803 | pBVI01 | Hypothetical protein | Function unknown |
| 29:B7 | CGGCTAGGCGGCCAGATCT | 2890 | chr1 | Inorganic ion transport and metabolism | |
| 27:G3 | CCCCCGCCGTACTAGTCGA | 5515 | chr3 | Posttranslational modification, protein turnover, chaperones | |
| 19:D4 | CTGCTCCGGCACGACGTCCA | 0426 | chr1 | DNA primase TraC | Replication, recombination and repair |
| 42:B11 | ATAATAGTCAAGGCGTGGCC | 6093 | chr3 | Transposase Tn | Replication, recombination and repair |
| 7:G7 | TGAGTTTAATGTCTTCGCT | 6805 | pBVIE01 | Putative signal transduction protein | Signal transduction mechanisms |
| 19:H7 | CCGACGCGCGCCGGCAGCG | 2370 | chr1 | Signal transduction mechanisms | |
| 35:G5 | CGTGACCAGGTGCTCGCGA | 3929 | chr2 | Integral membrane sensor hybrid histidine kinase | Signal transduction mechanisms |
| 8:D10 | GGCAGGCCAGATCTGATCA | 7553 | pBVIE04 | Helicase domain-containing protein | Transcription |
| 6:F4 | CGTGACGACCGAGTCGAAG | 3650 | chr2 | Chromosome replication initiation inhibitor protein | Transcription |
| 43:G1 | CGCTCACTGCCGGCCGGCAA | 4632 | chr2 | LysR-family transcriptional regulator | Transcription |
| 20:G12 | TACGACCAGTCTGCGAATCG | 3794 | chr2 | Transcription | |
| 22:E11 | TCAGCTAGGCGGCCAGATCT | 0918 | chr1 | Transcription, signal transduction mechanisms |
Putative function of poorly characterized proteins based on predicted protein-protein interactions networks in the STRING database (17).
Identified using the eggNOG database (65).
Mutant demonstrated a 4-fold decrease in MIC (0.0625% [wt/vol]) of HEPB by agar dilution assay. All other mutants demonstrated a 2-fold decrease in MIC of HEPB by agar dilution assay.